Day One Biopharmaceuticals (DAWN) Competitors $7.54 +0.14 (+1.82%) As of 12:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. HCM, KNSA, OGN, MLYS, ALVO, IBRX, BHC, CPRX, TARS, and IDYAShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include HUTCHMED (HCM), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Mineralys Therapeutics (MLYS), Alvotech (ALVO), ImmunityBio (IBRX), Bausch Health Cos (BHC), Catalyst Pharmaceuticals (CPRX), Tarsus Pharmaceuticals (TARS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors HUTCHMED Kiniksa Pharmaceuticals International Organon & Co. Mineralys Therapeutics Alvotech ImmunityBio Bausch Health Cos Catalyst Pharmaceuticals Tarsus Pharmaceuticals IDEAYA Biosciences HUTCHMED (NASDAQ:HCM) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership. Which has preferable earnings and valuation, HCM or DAWN? HUTCHMED has higher revenue and earnings than Day One Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$630.20M4.53$37.73MN/AN/ADay One Biopharmaceuticals$131.16M5.89-$95.50M-$0.95-7.94 Do analysts rate HCM or DAWN? HUTCHMED currently has a consensus price target of $20.88, indicating a potential upside of 27.64%. Day One Biopharmaceuticals has a consensus price target of $25.29, indicating a potential upside of 235.13%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Day One Biopharmaceuticals is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Day One Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Do institutionals and insiders have more ownership in HCM or DAWN? 8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is HCM or DAWN more profitable? HUTCHMED has a net margin of 0.00% compared to Day One Biopharmaceuticals' net margin of -50.63%. HUTCHMED's return on equity of 0.00% beat Day One Biopharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Day One Biopharmaceuticals -50.63%-19.01%-16.99% Which has more risk & volatility, HCM or DAWN? HUTCHMED has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.26, suggesting that its stock price is 226% less volatile than the S&P 500. Does the media prefer HCM or DAWN? In the previous week, HUTCHMED and HUTCHMED both had 2 articles in the media. Day One Biopharmaceuticals' average media sentiment score of 1.06 beat HUTCHMED's score of 0.13 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Day One Biopharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDay One Biopharmaceuticals beats HUTCHMED on 8 of the 14 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$771.71M$3.38B$6.14B$10.63BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-7.9321.7285.5327.24Price / Sales5.89476.93624.66138.72Price / CashN/A47.6737.7861.77Price / Book1.5110.2013.156.75Net Income-$95.50M-$52.22M$3.30B$276.53M7 Day Performance9.67%6.52%5.04%3.39%1 Month Performance1.00%14.84%9.78%9.84%1 Year Performance-44.89%28.97%87.35%35.49% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals3.0506 of 5 stars$7.55+1.8%$25.29+235.1%-45.4%$771.71M$131.16M-7.9360Positive NewsHCMHUTCHMED2.4303 of 5 stars$15.66+0.1%$20.88+33.3%-23.8%$2.73B$630.20M0.001,811KNSAKiniksa Pharmaceuticals International3.689 of 5 stars$38.77+6.2%$44.29+14.2%+60.6%$2.70B$423.24M969.49220Analyst DowngradeHigh Trading VolumeOGNOrganon & Co.4.7669 of 5 stars$10.35+1.3%$17.33+67.6%-41.5%$2.65B$6.40B3.854,000Positive NewsMLYSMineralys Therapeutics2.9338 of 5 stars$39.35-1.6%$43.50+10.5%+175.7%$2.65BN/A-11.0528Positive NewsALVOAlvotech3.9765 of 5 stars$8.40+0.7%$14.00+66.7%-31.2%$2.51B$560.10M36.521,032Gap UpIBRXImmunityBio2.6843 of 5 stars$2.57+1.2%$10.75+318.3%-28.4%$2.40B$14.74M-5.35590BHCBausch Health Cos4.6519 of 5 stars$6.47-0.2%$9.00+39.1%-21.6%$2.40B$9.63B24.8920,700CPRXCatalyst Pharmaceuticals4.8577 of 5 stars$19.55+0.2%$33.20+69.8%+5.5%$2.39B$491.73M11.8580Buyback AnnouncementTARSTarsus Pharmaceuticals0.7707 of 5 stars$58.08+3.2%$66.67+14.8%+106.0%$2.38B$182.95M-24.9350IDYAIDEAYA Biosciences4.1786 of 5 stars$27.19+1.3%$43.36+59.5%-8.5%$2.35B$7M-7.1780 Related Companies and Tools Related Companies HUTCHMED Competitors Kiniksa Pharmaceuticals International Competitors Organon & Co. Competitors Mineralys Therapeutics Competitors Alvotech Competitors ImmunityBio Competitors Bausch Health Cos Competitors Catalyst Pharmaceuticals Competitors Tarsus Pharmaceuticals Competitors IDEAYA Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredHow to profit from the AI maniaPorter Stansberry says the AI boom’s next trillion-dollar winners won’t be chatbots or Big Tech — but the over...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
